Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

Author： Mitsogiannis Iraklis C   Skolarikos Andreas   Deliveliotis Charalambos  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.3, 2009-02, pp. : 493-501

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)

By  

Current Cancer Drug Targets, Vol. 15, Iss. 3, 2015-05 ,pp. : 243-255

Bentham Science Publishers

Access to resources Recommend Favorite

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer

By Sharifi Nima  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 837-846

Informa Healthcare

Access to resources Recommend Favorite

Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer

By Twiddy Alexis   Leon Carlos   Wasan Kishor  

Pharmaceutical Research, Vol. 28, Iss. 3, 2011-03 ,pp. : 423-437

Springer Publishing Company

Access to resources Recommend Favorite

Sipuleucel-T: In Metastatic Castration-Resistant Prostate Cancer

By Plosker Greg L.  

Drugs, Vol. 71, Iss. 1, 2011-01 ,pp. : 101-108

Adis International

Access to resources Recommend Favorite

Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer

By Yang Lily P.H.  

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2067-2077

Adis International

Access to resources Recommend Favorite